JNCI Journal of the National Cancer Institute · 1987 · 134 citations · 0 references
Life SciencesInfectious DiseasesMolecular BiologyImmunopharmacologyMolecular VirologyVirologyAntiviral AgentsAntiviral ImmunityAntiviral PharmacologyAntiviral TherapyViral InfectionsViral PathogenesisAcquired Immunodeficiency SyndromeAntiviral Mechanisms Of ActionAntiviral TherapeuticsRetrovirus BiologyViral Polymerase InhibitorsViral Replication ControlViral Replication InhibitionViral Replication Inhibitors
Avarol and avarone are two antimitotic and antimutagenic agents that preferentially inhibit proliferation of T-cell leukemia lines in vitro. This report shows that these compounds have a dose-dependent inhibitory effect on the replication of the etiologic agent of acquired immune deficiency syndrome (AIDS), human T-lymphotropic retrovirus (HTLV-III)/lymphadenopathy-associated virus, in human H9 cells in vitro. Both compounds show a significant cytoprotective effect on HTLV-IIIB-infected H9 cells at concentrations as low as 0.1 microgram/ml (0.3 microM). Both avarone and avarol block in a dose-dependent manner the expression of the p24 and p17 gag proteins of HTLV-III in H9 cells after virus infection and block viral replication, as judged by approximately 80% inhibition of reverse transcriptase activity. These results strongly suggest that these compounds may prove to be useful in the treatment of patients with AIDS and AIDS-related complex.